Findings suggest COVID-19 rebound not caused by impaired immune response
Detailed analysis of eight patients published.
Related Articles
The HIV Field Needs Early-Stage Investigators (VIDEO)
The HIV research community is led by scientists with deep personal commitments to improving the lives of people with and affected by HIV. Our collective…
Children disproportionately wearing the scars of the war in Gaza – Geneva Palais briefing note
This is a summary of what was said by UNICEF Communication Specialist Tess Ingram – to whom quoted text may be attributed – at today’s…
Record Numbers in the US Are Homeless. Can Cities Fine Them for Sleeping in Parks and on Sidewalks?
The most significant case in decades on homelessness has reached the Supreme Court as record numbers of people in America are without a permanent place…
PEPFAR Reauthorization by Congress Urgent for Global Health
This Viewpoint discusses the importance of the US Congress reauthorizing funding for the President’s Emergency Plan for AIDS Relief, a program developed in 2003 that…
Should Patients with COVID-19 Who Are at Standard Risk Take Nirmatrelvir/Ritonavir?
U.S. National Institutes of Health guidelines currently recommend nirmatrelvir/ritonavir (Paxlovid) as first-line therapy for outpatients with COVID-19
Sexually Transmitted Infections—A Closer Look at NIAID Research
Sexually transmitted infections (STIs) are caused by bacteria, viruses, or parasites. NIAID supports research across the spectrum from basic to clinical science to develop effective…
Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial – CROI Conference
Background: Long-acting antiretroviral therapy (LA-ART) is novel and has been used for both virologically-suppressed (VS) and viremic patients with adherence challenges. The currently-approved LA-ART combination…
Aid ‘still not reaching Gaza’, as top US official warns famine has started
Samantha Power becomes first US official to confirm famine, while aid workers decry continuing lack of help
Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection
Despite the use of vaccines, seasonal influenza remains a risk to public health. We previously proposed the inactivated whole virus particle vaccine (WPV) as an…
Pfizer RSV shot meets goals in trial of high-risk adults under age 60
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the…